Walleye Capital
ABOS icon

Walleye Capital’s Acumen Pharmaceuticals ABOS Stock Holding History

Walleye Capital’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-18,801
Closed -$45.5K – 5188
2024
Q2 		$45.5K Buy
+18,801
New +$59.9K ﹤0.01% 4952
2023
Q2 		– Sell
-196,539
Closed -$798K – 4240
2023
Q1 		$798K Buy
196,539
+182,648
+1,315% +$954K 0.01% 1329
2022
Q4 		$75K Buy
+13,891
New +$93.3K ﹤0.01% 2437

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Walleye Capital's ABOS Position: Q3 2024 in Review

Walleye Capital sold out of Acumen Pharmaceuticals (ABOS) in Q3 2024, closing a stake of 18,801 shares — an estimated $45.5K sold.

Walleye Capital first reported a position in ABOS in Q4 2022 and held it in 3 quarters. The position peaked at $798K in Q1 2023. 73 funds tracked by Wall St. Rank hold ABOS as of Q3 2024.

  • Walleye Capital reported no remaining Acumen Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Walleye Capital sold 18,801 Acumen Pharmaceuticals shares in Q3 2024, an estimated $45.5K.
  • Walleye Capital first reported a position in Acumen Pharmaceuticals in Q4 2022 and held it in 3 quarters.
  • Walleye Capital's Acumen Pharmaceuticals position peaked at $798K in Q1 2023.
  • 73 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q3 2024.

Based on Walleye Capital's 13F filing for Q3 2024, filed 14 Nov 2024.